Aadi Bioscience is a biopharmaceutical company focused on developing and commercializing precision therapies targeted to rare mutation-driven diseases. Co.'s primary drug product, FYARRO, is nab-sirolimus (sirolimus protein-bound particles for injectable suspension (albumin-bound)) for diseases driven by the mTOR pathway activation through mutations or deletions of specific genes such as Tuberous Sclerosis Complex 1 and 2. FYARRO is licensed to Co. by Abraxis BioScience, LLC, a wholly owned subsidiary of Bristol Myers Squibb Company, for various therapeutic areas including oncology, cardiovascular, and metabolic related diseases. The AADI average annual return since 2018 is shown above.
The Average Annual Return on the AADI average annual return since 2018 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether AADI average annual return since 2018 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AADI average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|